Novo Nordisk 1Q Revenues: 53.4 DKK billion (+27%). $7.8 billion 1Q Earnings: 19.8 DKK billion (+39%) $2.9 billion Comments: Sales within Diabetes and Obesity care increased by 33% to DKK 48.8 billion, mainly driven by GLP-1 diabetes sales growth of 54%. Rare disease sales decreased 15% reflecting a temporary reduction in manufacturing output. Obesity care sales grew by 131% to DKK 7.8 billion mainly driven by the uptake of Wegovy in the U.S. A second contract manufacturer for Wegovy initiated...